These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37659418)

  • 1. Effect of 13-valent pneumococcal conjugate vaccine on experimental carriage of Streptococcus pneumoniae serotype 6B in Blantyre, Malawi: a randomised controlled trial and controlled human infection study.
    Dula D; Morton B; Chikaonda T; Chirwa AE; Nsomba E; Nkhoma V; Ngoliwa C; Sichone S; Galafa B; Tembo G; Chaponda M; Toto N; Kamng'ona R; Makhaza L; Muyaya A; Thole F; Kudowa E; Howard A; Kenny-Nyazika T; Ndaferankhande J; Mkandawire C; Chiwala G; Chimgoneko L; Banda NPK; Rylance J; Ferreira D; Jambo K; Henrion MYR; Gordon SB;
    Lancet Microbe; 2023 Sep; 4(9):e683-e691. PubMed ID: 37659418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A feasibility study of controlled human infection with Streptococcus pneumoniae in Malawi.
    Morton B; Burr S; Chikaonda T; Nsomba E; Manda-Taylor L; Henrion MYR; Banda NP; Rylance J; Ferreira DM; Jambo K; Gordon SB;
    EBioMedicine; 2021 Oct; 72():103579. PubMed ID: 34571365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of pneumococcal conjugate vaccine-13 on nasal colonisation in a controlled human infection model of pneumococcal carriage in Malawi: a double-blinded randomised controlled trial protocol.
    Morton B; Jambo K; Chikaonda T; Rylance J; Henrion MYR; Banda NP; Nsomba E; Gondwe J; Ferreira D; Gordon SB;
    Wellcome Open Res; 2021; 6():240. PubMed ID: 36263101
    [No Abstract]   [Full Text] [Related]  

  • 4. Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation.
    Tembo G; Mayuni M; Kamng'ona R; Chimgoneko L; Chiwala G; Sichone S; Galafa B; Thole F; Mkandawire C; Chirwa AE; Nsomba E; Nkhoma V; Ngoliwa C; Toto N; Makhaza L; Muyaya A; Kudowa E; Henrion MYR; Dula D; Morton B; Chikaonda T; Gordon SB; Jambo KC
    Vaccine; 2024 Apr; 42(12):2975-2982. PubMed ID: 38570270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pneumococcal controlled human infection model in Malawi: Transfer of an established pneumococcal carriage model from Liverpool, UK to Blantyre, Malawi - A feasibility study.
    Morton B; Burr S; Jambo K; Rylance J; Henrion MYR; Banda NP; Nsomba E; Kapumba B; Manda-Taylor L; Masesa C; Ferrreira D; Gordon SB;
    Wellcome Open Res; 2020; 5():25. PubMed ID: 32399498
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
    Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
    Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural carriage of Streptococcus pneumoniae is associated with increased experimental pneumococcal carriage but reduced conjugate vaccine efficacy in a human challenge model.
    Galafa B; Chikaonda T; Kudowa E; Sichone S; Sibale L; Thole F; Mkandawire C; Dula D; Nsomba E; Tembo G; Chaponda M; Chirwa AE; Nkhoma V; Ngoliwa C; Kamng'ona R; Toto N; Makhaza L; Muyaya A; Howard A; Nyazika TK; Ndaferankhande J; Chimgoneko L; Banda NPK; Chiwala G; Rylance J; Ferreira D; Jambo KC; Morton B; Henrion MYR; Gordon SB
    J Infect Dis; 2024 Jul; ():. PubMed ID: 38984706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
    Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK
    Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children.
    Lewnard JA; Givon-Lavi N; Dagan R
    Clin Infect Dis; 2020 Nov; 71(8):e289-e300. PubMed ID: 31784753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the 13-valent pneumococcal conjugate vaccine on Streptococcus pneumoniae multiple serotype carriage.
    Valente C; Hinds J; Gould KA; Pinto FR; de Lencastre H; Sá-Leão R
    Vaccine; 2016 Jul; 34(34):4072-8. PubMed ID: 27325351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pragmatic health centre-based evaluation comparing the effectiveness of a PCV13 schedule change from 3+0 to 2+1 in a high pneumococcal carriage and disease burden setting in Malawi: a study protocol.
    Swarthout TD; Ibarz-Pavon A; Kawalazira G; Sinjani G; Chirombo J; Gori A; Chalusa P; Bonomali F; Nyirenda R; Bulla E; Brown C; Msefula J; Banda M; Kachala J; Mwansambo C; Henrion MY; Gordon SB; French N; Heyderman RS
    BMJ Open; 2021 Jun; 11(6):e050312. PubMed ID: 34140345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2).
    Liatsikos K; Hyder-Wright A; Pojar S; Chen T; Wang D; Davies K; Myerscough C; Reine J; Robinson RE; Urban B; Mitsi E; Solorzano C; Gordon SB; Quinn A; Pan K; Anderson AS; Theilacker C; Begier E; Gessner BD; Collins A; Ferreira DM;
    BMJ Open; 2022 Jul; 12(7):e062109. PubMed ID: 35798520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study.
    Swarthout TD; Henrion MYR; Thindwa D; Meiring JE; Mbewe M; Kalizang'Oma A; Brown C; Msefula J; Moyo B; Mataya AA; Barnaba S; Pearce E; Gordon M; Goldblatt D; French N; Heyderman RS
    Lancet Infect Dis; 2022 Dec; 22(12):1737-1747. PubMed ID: 36029796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of high residual post-PCV13 pneumococcal vaccine-type carriage in Blantyre, Malawi: a modelling study.
    Lourenço J; Obolski U; Swarthout TD; Gori A; Bar-Zeev N; Everett D; Kamng'ona AW; Mwalukomo TS; Mataya AA; Mwansambo C; Banda M; Gupta S; French N; Heyderman RS
    BMC Med; 2019 Dec; 17(1):219. PubMed ID: 31801542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumococcal carriage in households in Karonga District, Malawi, before and after introduction of 13-valent pneumococcal conjugate vaccination.
    Heinsbroek E; Tafatatha T; Phiri A; Swarthout TD; Alaerts M; Crampin AC; Chisambo C; Mwiba O; Read JM; French N
    Vaccine; 2018 Nov; 36(48):7369-7376. PubMed ID: 30352744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
    Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
    Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single priming and booster dose of ten-valent and 13-valent pneumococcal conjugate vaccines and Streptococcus pneumoniae colonisation in children in South Africa: a single-centre, open-label, randomised trial.
    Olwagen CP; Izu A; Mutsaerts EAML; Jose L; Koen A; Downs SL; Van Der Merwe L; Laubscher M; Nana AJ; Moultrie A; Cutland CL; Dorfman JR; Madhi SA
    Lancet Child Adolesc Health; 2023 May; 7(5):326-335. PubMed ID: 36934731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High multiple carriage and emergence of Streptococcus pneumoniae vaccine serotype variants in Malawian children.
    Kamng'ona AW; Hinds J; Bar-Zeev N; Gould KA; Chaguza C; Msefula C; Cornick JE; Kulohoma BW; Gray K; Bentley SD; French N; Heyderman RS; Everett DB
    BMC Infect Dis; 2015 Jun; 15():234. PubMed ID: 26088623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumococcal carriage in vaccine-eligible children and unvaccinated infants in Lao PDR two years following the introduction of the 13-valent pneumococcal conjugate vaccine.
    Satzke C; Dunne EM; Choummanivong M; Ortika BD; Neal EFG; Pell CL; Nation ML; Fox KK; Nguyen CD; Gould KA; Hinds J; Chanthongthip A; Xeuatvongsa A; Mulholland EK; Sychareun V; Russell FM
    Vaccine; 2019 Jan; 37(2):296-305. PubMed ID: 30502068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.